

**Name** **WALCZAK, Henning, Prof. Dr. rer. nat.**  
10.02.1066, German, male  
**Address** Universität zu Köln, Center of Biochemistry & CECAD Research Center  
Joseph-Stelzmann-Str. 26, 50931 Köln|  
Phone: +49 (0) 221 4788 4076  
E-mail: h.walczak@uni-koeln.de  
**Position:** Professor of Biochemistry (W3)  
**Children:** 3 children, no period of childcare leave



### Academic education

1991 - 1992 Diploma thesis work performed at Tumour Immunology Programme of the Cancer Research Centre (DKFZ), Heidelberg, Germany  
1986 - 1991 Studies of Biology at the University of Bielefeld

### Scientific degrees

June 1995 Dr. rer. nat. (Ph.D.) degree received from University of Bielefeld, Germany with "summa cum laude" for thesis work performed at DKFZ  
1992 - 1995 Ph.D. thesis in the Department of Immunogenetics (Head: Peter H. Krammer), Tumour Immunology Programme, DKFZ; Title: Molecular and functional characterisation of the APO-1 ligand  
June 1992 Diploma in Biology (Master's Degree) received from University of Bielefeld with grade: "very good"

### Scientific career

2019 - present Alexander von Humboldt Professor of Biochemistry and Director of the Center for Biochemistry, Medical Faculty, University of Cologne, Germany  
2014 - 2019 Head of the Department of Cancer Biology, UCL Cancer Institute, University College London, London, UK  
2013 - 2019 Scientific Director, CRUK – UCL Cancer Centre  
2013 - present Professor of Cancer Biology and Chair of Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute  
2007 - 2012 Professor of Tumour Immunology, Head of Tumour Immunology Unit, Imperial College London, London, UK  
2000 - 2007 Head of the BioFuture Research Group "Apoptosis Regulation" within the Tumour Immunology Programme of the German Cancer Research Centre (DKFZ), Heidelberg, Germany  
2002 - 2004 CEO/CSO of Apogenix, a biotech company dedicated to developing targeted pro- and anti-apoptotic therapeutics (during this period the position at DKFZ was part time)  
1998 - 2000 Group Leader in the Department of Immunogenetics of the Tumour Immunology Programme of the DKFZ  
1996 - 1997 Scientist (PostDoc Level) at Immunex Corp. in Seattle, WA, USA  
1995 - 1996 Postdoctoral Fellow in the Tumour Immunology Programme of the DKFZ

### Honors/ Awards/ Memberships

2019 Alexander von Humboldt Professorship Prize  
2018 Wellcome Trust Investigator Award  
2013 - present Member of the ERC Consolidator Grants Life Sciences 4 (ERC CoG LS4) Panel  
2011 Wellcome Trust Investigator Award  
2011 ERC Advanced Grant  
2001 genius biotech award for the business plan of Apogenix AG (1st Prize)  
1999 BioFuture Prize of the German Ministry of Education and Science (BMBF)  
1996 5-year Postdoctoral Fellowship for Research on Infectious Diseases ('Aids Stipend Programme) awarded by the German Ministry for Science and Technology (BMWT)

### 10 most relevant publications

1. Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, Hassan O, Kitzig E, Müller I, El-Bahrawy MA, von Karstedt S, Kulms D, Liccardi G, Lemke J, **Walczak H**. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. *Cell Death Differ*. 29:492-503, 2022.

2. Lafont, E., Draber, P., Rieser, E., Reichert, M., Kupka, S., de Miguel, D., Draberova, H., von Mässenhausen, A., Bhamra, A., Henderson, S., Wojdyla, K., Chalk, A., Surinova, S., Linkermann, A., **Walczak, H.** (2018). TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. *Nature Cell Biology* 20:1389-1399, 2018.
3. Taraborrelli, L., Peltzer, N., Montinaro, A., Kupka, S., Rieser, E., Hartwig, T., Sarr, A., Darding, D., Draber, P., Haas, T.L., Akarca, A., Marafioti, T., Pasparakis, M., Bertin, J., Gough, P.J., Bouillet, P., Strasser, A., Leverkus, M., Silke, S., **Walczak, H.** LUBAC prevents lethal dermatitis by combined inhibition of TNF-, TRAIL- and CD95L-mediated cell death. *Nature Communications* 9:3910, 2018.
4. Peltzer, N., Darding, M., Montinaro, A., Draber, P., Draberova, H., Kupka, S., Rieser, E., Fisher, A., Hutchinson, C., Taraborrelli, L., Hartwig, t., Lafont, E., Haas, T.L., Shimizu, Y., Böiers, C., Sarr, A., Rickard, J., Alvarez-Diaz, S., Ashworth, M.T., Beal, A., Enver, T., Bertin, J., Kaiser, W., Strasser, A., Silke, J., Bouillet, P., **Walczak, H.** LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. *Nature* 557:112-117, 2018.
5. Hartwig, T., Montinaro, A., von Karstedt, S., Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., El-Bahrawy, M.A., Quezada, S.A., **Walczak, H.** The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. *Molecular Cell* 65:730-742, 2017.
6. Lafont, E., Kantari-Mimoun, C., Draber, P., De Miguel, D., Hartwig, T., Reichert, M., Kupka, S., Shimizu, Y., Taraborrelli, L., Spit, M., Sprick, MR., **Walczak, H.** The linear ubiquitin chain assembly complex regulates TRAIL- induced gene activation and cell death. *EMBO Journal* 36:1147-1166, 2017.
7. Von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A.D., Taraborrelli, L., Grosse-Wilde, A., Coy, J.F., El-Bahrawy, M.A., Bergmann, F., Koschny, R., Werner, J., Ganten, T.M., Schweiger, T., Hoetzenecker, K., Kenessey, I., Hegedüs, B., Bergmann, M., Hauser, C., Egberts, J.H., Becker, T., Röcken, C., Kalthoff, H., Trauzold, A., Anderson, K.I., Sansom, O.J., **Walczak, H.** Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. *Cancer Cell*, 27 561-73, 2015.
8. Peltzer, N., Rieser, E., Taraborrelli, L., Draber, P., Darding, M., Pernaute, B., Shimizu, Y., Daboh, A., Draberova, H., Montinaro, A., Martinez-Barbera, J.P., Silke, J., Rodriguez, T.A. and **Walczak, H.** HOIP deficiency caused embryonic lethality by aberrant TNFR1-mediated endothelial cell death. *Cell Reports* 9:153-165, 2014.
9. Lemke, J., von Karstedt, S., Abd El Hay, M., Conti, A., Arce, F., Montinaro, A., Papenfuss, K., El-Bahrawy, M.A., **Walczak, H.** Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFLIP and Mcl-1. *Cell Death and Differ* 21:491-502, 2014.
10. Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, A.I., Rickard, J.A., Anderton, H., Wong, W.W.-L., Nachbur, U., Gangoda, L., Warnken, U., Purcell, A.W., Silke, J., **Walczak, H.** Linear ubiquitination prevents inflammation and regulates immune signalling. *Nature* 471:591-596, 2011.